期刊
BIOMED RESEARCH INTERNATIONAL
卷 2016, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2016/8265907
关键词
-
资金
- scholarly public grant, named Capital Featured Clinical Application Research Project [Z151100004015171]
The aim of this study is to evaluate the feasibility, safety, and clinical efficacy of CT-guided I-125 seed interstitial brachytherapy in patients with recurrent spinal metastases after external beam radiotherapy (EBRT). Between August 2003 and September 2015, 26 spinal metastatic lesions (24 patients) were reirradiated by this salvage therapy modality. Treatment for all patients was preplanned using a three-dimensional treatment planning system 3-5 days before I-125 seed interstitial brachytherapy; dosimetry verification was performed immediately after seed implantation. Median actual D-90 was 99 Gy (range, 90-176), and spinal cord median D-max was 39 Gy (range, 6-110). Median local control (LC) was 12 months (95% CI: 7.0-17.0). The 6-and 12-month LC rates were 52% and 40%, respectively. Median overall survival (OS) was 11 months (95% CI: 7.7-14.3); 6- month and 1-, 2-, and 3-year OS rates were 65%, 37%, 14%, and 9%, respectively. Pain-free survival ranged from 2 to 42 months (median, 6; 95% CI: 4.6-7.4). Treatment was well-tolerated, with no radiation-induced vertebral compression fractures or myelopathy reported. Reirradiation with CT-guided I-125 seed interstitial brachytherapy appears to be feasible, safe, and effective as pain relief or salvage treatment for patients with recurrent spinal metastases after EBRT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据